A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement	FGFR2 Gene Fusion/Rearrangement; Other Solid Tumors, Adult	Recruiting	Phase 2	2026-09-03		NCT07359820

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Elevar Therapeutics	1

19 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Georges François Leclerc	Dijon	France	42
Centre Leon Berard	Lyon	France	70
Gustave Roussy Cancer Campus	Paris	France	1
Hospital Universitario Fundación Jiménez Díaz- START MADRID	Madrid	Spain	1
Hospital Universitario HM Sanchinarro-START MADRID-CIOCC	Madrid	Spain	1
Institut Bergonie	Bordeaux	France	53
Massachusetts General Hospital	Boston	United States	1015
Mayo Clinic	Rochester	United States	664
Mayo Clinic	Phoenix	United States	50
Mayo Clinic	Jacksonville	United States	122
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Moffitt Cancer Center	Tampa	United States	523
Samsung Medical Center	Seoul	South Korea	375
Sarah Cannon Research Institute UK	London	United Kingdom	26
Seoul National University Hospital	Seoul	South Korea	393
START Barcelona-Hospital HM Nou Delfos	Barcelona	Spain	1
The Christie NHS Foundation	Manchester	United Kingdom	1
The University of Texas M.D. Anderson Cancer Center	Houston	United States	18
University of Chicago Medical Center	Chicago	United States	152